Preincubation in the prothrombinase-induced clotting time test (PiCT) is necessary for in vitro evaluation of fondaparinux and to be avoided for the reversible, direct factor Xa inhibitor, rivaroxaban

International Journal of Laboratory Hematology

Volumn 35, Issue 4, 2013, Pages 379-384

  Kluft, C ^a,b   Meijer, P ^b   Kret, R ^b   Burggraaf, J ^a  

^a CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

^b Good Biomarker Sciences   (Netherlands)

Author keywords

Clotting test; Coagulation; Fondaparinux; PiCT; Rivaroxaban

Indexed keywords

BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; FONDAPARINUX; RIVAROXABAN;

ARTICLE; ARTIFACT; AUTOMATION; BLOOD CLOTTING TIME; CALCIFICATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; FIBRIN FORMATION; IN VITRO STUDY; INCUBATION TIME; LABORATORY AUTOMATION; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBINASE INDUCED CLOTTING TEST;

CLOTTING TEST; COAGULATION; FONDAPARINUX; PICT; RIVAROXABAN;

ANTICOAGULANTS; BIOLOGICAL ASSAY; BLOOD COAGULATION; FACTOR XA; HUMANS; KINETICS; MORPHOLINES; PARTIAL THROMBOPLASTIN TIME; POLYSACCHARIDES; THIOPHENES; THROMBOPLASTIN; TIME FACTORS;

EID: 84880602190     PISSN: 17515521     EISSN: 1751553X     Source Type: Journal    
DOI: 10.1111/ijlh.12027     Document Type: Article

References (13)

1. Bauer KA. New pentasaccharides for prophylaxis of deep vein thrombosis: pharmacology. Chest 2003;124:364S-70S.
2. Samama MM, Gerotziafas GT, Elalamy I, Horellou MH, Conard J. Biochemistry and clinical pharmacology of new anticoagulant agents. Pathophysiol Haemost Thromb 2002;32:218-24.
3. Brufatto N, Ward A, Nesheim ME. Factor Xa is highly protected from antithrombin-fondaparinux and antithrombin-enoxaparin when incorporated into the prothrombinase complex. J Thromb Haemost 2003;1:1258-63.
4. Linkins LA, Julian JA, Rischke J, Hirsh J, Weitz JI. In vitro comparison of the effect of heparin, enoxaparin and fondaparinux on tests of coagulation. Thromb Res 2002;107:241-4.
5. Smogorzewska A, Brandt JT, Chandler WL, Cunningham MT, Hayes TE, Olson JD, Kottke-Marchant K, Cott Van EM. Effect of fondaparinux on coagulation assays: results of College of American Pathologists proficiency testing. Arch Pathol Lab Med 2006;130:1605-11.
6. Walenga JM, Bara L, Petitou M, Samama M, Fareed J, Choay J. The inhibition of the generation of thrombin and the antithrombotic effect of a pentasaccharide with sole anti-factor Xa activity. Thromb Res 1988;51:23-33.
7. Walenga JM, Jeske WP, Bara L, Samama MM, Fareed J. Biochemical and pharmacologic rationale for the development of a synthetic heparin pentasaccharide. Thromb Res 1997;86:1-36.
8. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939-an oral, direct Factor Xa inhibitor-after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 2005;61:873-80.
9. Calatzis A, Peetz D, Haas S, Spannagl M, Rudin K, Wilmer M. Prothrombinase-induced clotting time assay for determination of the anticoagulant effects of unfractionated and low-molecular-weight heparins, fondaparinux, and thrombin inhibitors. Am J Clin Pathol 2008;130:446-54.
10. Harder S, Parisius J, Picard-Willems B. Monitoring direct FXa-inhibitors and fondaparinux by Prothrombinase-induced Clotting Time (PiCT): relation to FXa-activity and influence of assay modifications. Thromb Res 2008;123:396-403.
11. Harenberg J, Giese C, Hagedorn A, Traeger I, Fenyvesi T. Determination of antithrombin-dependent factor Xa inhibitors by prothrombin-induced clotting time. Semin Thromb Hemost 2007;33:503-7.
12. Graff J, Picard-Willems B, Harder S. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a. Int J Clin Pharmacol Ther 2007;45:237-43.
13. Keam SJ, Goa KL. Fondaparinux sodium. Drugs 2002;62:1673-85; discussion 1686-7.